Immune SupportAvailable
KPV
A tripeptide fragment of alpha-MSH studied for anti-inflammatory signalling.
Immune SupportHealing
Clinical review required · Pricing after approval
LL-37
A human antimicrobial peptide studied in innate immune defence and wound repair.
AvailableClinical review requiredPricing released after approval
Immune SupportHealing
What it is
LL-37 is the active form of the human cathelicidin antimicrobial peptide.
How it works
It has direct antimicrobial activity and modulates innate immune signalling and epithelial repair.
Why it may be considered
Considered narrowly, in specific clinical pictures, and never as a general immune tonic.
Who may be a candidate
- You are an established MECCA patient, or are willing to begin with a consultation.
- You have a clearly defined goal that this therapy plausibly addresses.
- Your recent laboratory work and history have been reviewed by your clinician.
- You are able to attend the monitoring intervals the protocol requires.
Who may not be a candidate
- You are pregnant, breastfeeding, or planning pregnancy.
- You have an active malignancy or an unresolved undiagnosed symptom.
- You take a medication that interacts with this therapy.
- Your goal is better served by training, nutrition, sleep or an existing prescription.
Typical treatment-review considerations
- Current medications, supplements and prescriptions written elsewhere.
- Relevant baseline testing, and whether an interval draw is needed first.
- Monitoring cadence, expected review date and the criteria for stopping.
- Whether a non-pharmacologic route addresses the same goal first.
Safety considerations
- Prescription-only. Never self-source or self-administer outside a supervised plan.
- Injection-site reactions, bruising and transient discomfort are the most commonly reported effects.
- Report any new or unexpected symptom to your care team before the next scheduled dose.
Frequently asked
About LL-37.
You can submit a request, but it cannot be approved until a licensed clinician has reviewed your history. If you are not yet a patient, your request opens a consultation rather than a prescription.
No. Pricing is released with your approved plan, after a clinician has decided the therapy is appropriate for you.
Often, yes. A request tells us what you are interested in. The recommendation you receive reflects your goals, history, medications and testing.
Related products
Considered alongside this therapy.
Immune SupportAvailable
Thymosin Alpha-1
An immune peptide studied in this category, with approved use in several countries.
Immune SupportLongevity
Clinical review required · Pricing after approval
Immune SupportAvailable
Thymalin
A thymic peptide complex studied for immune regulation in older adults.
Immune SupportLongevity
Clinical review required · Pricing after approval
Related education
What to understand before you request this.
How we think about safety.
Prescription therapy carries risk. We name the monitoring a therapy requires, the symptoms that should stop it, and the criteria for reviewing it again.
Read the medical disclaimer →How MECCA approaches therapy.
Measure, interpret, intervene, re-measure. Nothing is prescribed without a baseline, a defined goal and a scheduled point at which the plan is revisited.
Learn our approach →What happens after you request.
A request opens a clinical conversation. A licensed clinician decides what is appropriate, and pricing is released only with an approved plan.
See how ordering works →Clinical-review disclaimer — This page is educational and is not medical advice, a recommendation, or an offer to sell. No therapy described here can be dispensed without a prescription from a licensed clinician who has reviewed your history. MECCA does not publish dosing instructions or patient pricing, and requesting a product does not guarantee approval.
Begin with a conversation
A thirty-minute consultation, with a physician, at no cost.
We'll talk through your history and goals and tell you honestly whether MECCA is the right fit. No pressure, no packages, no obligation.